Applying DDX3X Biomarker to Discriminate Atypical from Benign Meningiomas in Tissue Microarray
In conclusion, DDX3X immunohistochemistry combined with hematoxylin and eosin staining may help differentiate atypical meningiomas from benign meningeal tumors.
Source: Applied Immunohistochemistry and Molecular Morphology - Category: Chemistry Tags: Research Articles Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Chemistry | International Medicine & Public Health | Men | Neurology | Study | WHO